Disease relevance of Nesidioblastosis

• We treated a two-month-old infant with servere intractable hypoglycemia and nesidioblastosis with continuous glucose infusions (0.75 g per kilogram per hour) via a central venous catheter [1].
• The results show that, in the BOP hamster model, islets are the site of formation of the major fraction of exocrine pancreatic cancer and that induction of nesidioblastosis enhances pancreatic carcinogenesis [2].
• One patient with nesidioblastosis had no response to secretin, indicating that the pathophysiology of this entity is distinct from that of other forms of islet hyperplasia [3].
• Medullary carcinoma of the thyroid, pancreatic nesidioblastosis and microadenosis, and pancreatic polypeptide hypersecretion: a new association and clinical and hormonal responses to long-acting somatostatin analog SMS 201-995 [4].
• Three cases in which seizure disorder was first noticed were examined in the last seven years; low fasting glucose and high serum insulin levels then led to the diagnosis of severe hypoglycemia secondary to nesidioblastosis [5].

High impact information on Nesidioblastosis

• Long-term treatment of an infant with nesidioblastosis using a somatostatin analogue [6].
• The purpose of this study was to determine whether the induction of nesidioblastosis could be used as a means of reversing streptozocin-induced diabetes [7].
• The concentrations of 7B2 in pancreatic islet tumors and in nesidioblastosis were investigated also [8].
• Deficient insulin release causes hyperglycemia and diabetes, whereas excessive insulin release can give rise to serious metabolic disorders, such as nesidioblastosis (Persistent Hyperinsulinemic Hypoglycemia of Infancy, PHHI) and might also be closely associated with development of type 2 diabetes and obesity [9].
• Overexpression of IGF-II or IGFBP-I can result in nesidioblastosis [10].

Chemical compound and disease context of Nesidioblastosis

• Short-term management of nesidioblastosis using the somatostatin analogue SMS 201-995 [11].
• Nesidioblastosis in a young woman and the impact of hyperinsulinaemia on triglyceride metabolism [12].
• INTERVENTIONS: Seventy percent distal pancreatectomy for all patients with nesidioblastosis, and maintenance therapy with verapamil hydrochloride for 2 patients [13].
• Hyperinsulinaemic hypoglycaemia due to chlorpropamide-induced nesidioblastosis [14].
• Alloxan therapy for nesidioblastosis [15].

Biological context of Nesidioblastosis

• Normalization of glucose homeostasis by a long-acting somatostatin analog SMS 201-995 in a newborn with nesidioblastosis [16].

Anatomical context of Nesidioblastosis

• Furthermore, the Ki-67 positivity was not more prominent in small clusters of B cells in nesidioblastosis than in large islets [17].
• Impaired expression of transcription factor IUF1 in a pancreatic beta-cell line derived from a patient with persistent hyperinsulinaemic hypoglycaemia of infancy (nesidioblastosis) [18].

Gene context of Nesidioblastosis

• A neonate with nesidioblastosis maintained normal blood glucose levels while receiving SMS 201-995 therapy following a 95 percent pancreatic resection [19].
• We herein describe two unique patients with adult nesidioblastosis with gastrin and pancreatic polypeptide secretion [20].
• Medical treatment with glucagon, somatostatin, and diazoxide led to only a modest reduction in the intravenous glucose requirement; a 95% pancreatectomy was performed and histological 'nesidioblastosis' confirmed [21].
• The proliferating cell nuclear antigen (PCNA) and Ki-67 indices were less than 4% in the nesidioblastosis [22].
• Adult onset nesidioblastosis: response of glucose, insulin, and secondary peptides to therapy with Sandostatin [23].

Analytical, diagnostic and therapeutic context of Nesidioblastosis

• Octreotide, administered by continuous intravenous infusion or intermittent bolus dosing, was used in the treatment of gastrointestinal bleeding in four patients, pancreatitis in three patients, chylous leaks in two patients, and hypoglycemia related to nesidioblastosis in one patient [24].

References